ZOETIS INC. (ZTS) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry...
ZOETIS INC. (ZTS) currently trades at a P/E ratio of 12.54 (historical range: 10.94–59.46, median: 34.31), placing it at the 7th percentile — cheap relative to its history, P/S ratio of 3.45 (range: 3.01–15.48, 7th percentile — cheap relative to its history), EV/EBITDA of 11.60 (range: 10.40–50.45, 6th percentile).
Over the historical period (2021-09-14 to 2026-10-16), ZOETIS INC.'s P/E ratio has contracted by 37% over the observed period (from an average of 40.2 to 25.3).
ZOETIS INC. trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 12.54 | 34.31 | 7th | cheap relative to its history |
| P/S Ratio | 3.45 | 9.11 | 7th | cheap relative to its history |
| EV/EBITDA | 11.60 | 28.94 | 6th | cheap relative to its history |
| FCF Yield | 7.21% | 2.15% | 94th | cheap relative to its history |
ZOETIS INC. (ZTS) Valuation & P/E History
ZOETIS INC. (ZTS) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry currently trading at $80.00 with a market capitalization of $33.1 billion. This page provides historical valuation analysis for ZTS based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 12.54 is below the historical median of 34.31, placing ZTS at the 7th percentile of its valuation range. The P/S ratio of 3.45 compares to a median of 9.11.
ZTS Valuation Metrics & Historical Range
The valuation table above shows ZOETIS INC.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether ZTS is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests ZTS is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for ZOETIS INC..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is ZTS Overvalued or Undervalued?
ZOETIS INC. trades well below its historical valuation range across most metrics. The overall valuation percentile of 7 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive ZTS is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full ZTS analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.ZTS trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.